Limited coverage criteria – riociguat

Generic name

riociguat

Strength & form

0.5 mg, 1 mg, 1.5 mg, 2 mg, 2.5 mg tablets

For the treatment of chronic thromboembolic pulmonary hypertension (CTEPH)¹ in adult patients ≥ 18 years of age who meet the following criteria:

• The patient is diagnosed with inoperable CTEPH² (World Health Organization [WHO] Group 4) with Functional Class (FC) II or III pulmonary hypertension

OR

• The patient has persistent or recurrent CTEPH after surgical treatment with WHO FC II or III pulmonary hypertension

AND

• Requests must be submitted by a cardiologist or respirologist with experience in the diagnosis and treatment of CTEPH

1 year